Recent investigations of medications, diet and the molecular understanding of prostate cancer are defining potential prevention strategies for the disease, and herald a new stage in the management of this cancer, according to a new review.
Writing in the November 1, 2007 issue of Cancer, Dr. Neil Fleshner and Dr. Alexandre Zlotta from the University of Toronto say that available medications, such as 5-alpha reductase inhibitors and selective estrogen receptor modifiers, show promise in reducing malignancies. In addition, there is strong evidence that dietary fat significantly impacts disease development and promising data that other compounds, such as soy, selenium and green tea, offer additional possibilities for disease prevention.
To read entire article in Science Daily click here.
There is additional information from WebMD. Click here to read article.
And one would surmise that if 5AR inhibitors serve to reduce malignancies, they would serve to complement other medications prescribed in androgen deprivation therapy. The challenge now is to get men not yet diagnosed with prostate cancer to pay attention to these recommendations to prevent development.
I´m presribing dutasteride to male relatives of my prostate cancer patients. Besides anual or bianual chek up I´m positive they are taking advantage having this medication.
Fernando Premoli MD PhD
Specializing on prostate cancer